Menu
Menu
Bringing the Power of AI to Early Cancer Detection
Detecting 6+ cancer types
OneTest is now available Globally
Now clinics and other medical providers can easily start offering A.I. based cancer screening with OneTest today using a cloud accessible portal.
Integration into existing biomarker based cancer screening programs
Adoption as a new stand-alone cancer screening offering
What is OneTest?
OneTestTM is among the first multi-cancer screening panels to harness the power of Ai to improve the accuracy and usefulness of affordable tumor marker tests to help identify 6 or more types of cancer.
Based on commonly ordered tumor markers such as PSA, CEA, AFP, CA-125 and others, OneTest can aid in the early detection of many types of cancer, including those not typically screen for such as lung, liver, pancreas, etc. OneTestTM is powered by real-world cancer-screening results of tens of thousands of people and is poised for continuous learning and advancement as the algorithms are exposed to more real-world data.
Multi-cancer screening that assesses risk for more than 6 common cancers.
Allows patients to track and manage their cancer marker value regardless of which doctor they use.
OneTest Improves Cancer Screening
AI
OneTest uses cutting edge artificial intelligence and big data to dramatically enhance test sensitivity and early detection
Cancer Risk Management
One of a kind Biomarker velocity tracking graph which allows health care professionals and patients to visualize deviations in biomarker levels to assist in cancer detection through serial testing.
Oncomarkers
OneTest’s biomarker panel consists of well established and readily available markers used by tens of millions of people per-year for screening in Asia
Affordability
OneTest is highly affordable, because it relies on a locally executed blood analysis, which allows for patient price flexibility to be determined by the local market
No Radiation
OneTest relies on blood based biomarkers for screening rather than invasive or harmful radiation imaging
Male
Biomarker
only 40.3%
only 40.3%
With AI
82.3%
Female
11.5%
With AI
74.8%
Improved Sensitivity
OneTestTM can significantly increase cancer detection rates by identifying important patterns in tumor marker results, which might fall below the standard manufacturers cutoff values.
How does OneTest Work?
1
Analyze blood specimen for tumor markers on Roche, Abbott, or other approved instrument
2
Complete patient health history via a 3-minute online questionnaire
3
Generate Onetest report by entering relevant health history and biomarker results into OneTest cloud algorithm
4
Follow up with appropriate diagnostic imaging or repeat OneTest, if needed
1
Analyze blood specimen for tumor markers on Roche, Abbott, or other approved instrument
2
Complete patient health history via a 3-minute online questionnaire.
3
Generate Onetest report by enter health history and biomarker results into OneTest cloud algorithm
4
Follow up with appropriate diagnostic imaging or repeat OneTest, if needed.
Who is OneTest For?
Access to the OneTest portal is available anywhere in the world through various models of subscription agreements
Hospitals
Hospitals, large or small can offer OneTest as part of their outpatient services
Clinics
A wide range of clinics can help draw in new patients by introducing them to OneTest's cutting edge technology
Health Check Centers
Health check centers offering advanced physicals are ideal candidates to include OneTest into their spectrum of options
Labs
Labs can easily integrate OneTest into their offering for both B2B and B2C
Medical Business
Other medical business have had success introducing OneTest into new markets
OneTest has been adopted for use in these countries
Contact us if you are interested in offering OneTest today
USA
Japan
Korea
UAE
Argentina
Taiwan
China
Jordan
Austria
Compatibility
OneTest has been validated to run using the results of these laboratory instrument platforms.
Required Biomarkers
Male Panel (6 markers)
AFP, CEA, CA 19-9, CYFRA 21-1, SCC, PSA
Female Panel (7 markers)
AFP, CEA, CA 19-9, CYFRA 21-1, SCC, CA 125, CA 15-3
Compatible Instruments
Abbott Architect i2000
Roche Elecsys Cobas
Siemens Advia Centaur
Beckman UniCel Dxl 800
OneTest by 2020 GeneSystems
20/20 is a USA-based cancer diagnostics company, which develops cancer diagnostic products since 2008. It has created proprietary tests for lung and other types of cancer and operates a CLIA certified laboratory, catering to the needs of American based patients and clinics.